Isofagomine and its Impurities
The treatment failed a clinical trial and is no longer under development. It is an experimental therapy that was developed by Amicus Therapeutics to treat Gaucher disease.Reference standards of Isofagomine API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.
Benzyl 2,3-O-[(1S,2S)-1,2-Dimethoxy-1,2-dimethyl-1,2-ethanediyl]-4-nitrobenzoyl-α-L-xylopyranoside
Benzyl 2,3-O-[(1S,2S)-1,2-Dimethoxy-1,2-dimethyl-1,2-ethanediyl]-4-nitrobenzoyl-α-L-xylopyranoside
Catalogue No.:PA 09 0831001
CAS :
1084896-42-3
Molecular Formula : C25H29NO10
Molecular Weight : 503.5
(2S,3S,4aR,8R,8aR)-Octahydro-2,3-dimethoxy-2,3-dimethyl-1,4-dioxino[2,3-c]pyridine-8-methanol
(2S,3S,4aR,8R,8aR)-Octahydro-2,3-dimethoxy-2,3-dimethyl-1,4-dioxino[2,3-c]pyridine-8-methanol
Catalogue No.:PA 09 0831002
CAS :
1084896-52-5
Molecular Formula : C12H23NO5
Molecular Weight : 261.32
